title: Current guidelines in heart failure management.
abstract: 1. ACE inhibitors are indicated for Class I-IV HF due to LVSD. 2. ARBs are recommended for HF patients with contra-indications or intolerance to ACE inhibitors. 3. Spironolactone provides additional benefit for Class IV HF patients. 4. Beta-blockers (carvedilol or long-acting metoprolol) are indicated as additive treatment to an ACE inhibitor or ARB for Class II or III HF. 5. The beta-blocker carvedilol has been found to be safe and effective in patients with severe HF and appears to improve clinical outcomes in patients with LVSD post-MI.
authors.affiliation: Department of Medicine, University of Texas, MD Anderson Cancer Center, Houston, USA. jdurand@mdanderson.org
authors.forename: Jean-Bernard
authors.initials: JB
authors.lastname: Durand
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D002316:Cardiotonic Agents / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004032:Diet; D015444:Exercise; D005260:Female; D006333:Heart Failure / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D011379:Prognosis; D012307:Risk Factors; D012720:Severity of Illness Index; D017678:Sex Distribution; D016540:Smoking Cessation; D015996:Survival Rate
chemical_list: D002316:Cardiotonic Agents